Senior BioPharma Business Development Executives Join Extera Partners
Friday, June 10, 2011
BOSTON– Extera Partners, a global life sciences management firm, announced today that Jefferson Davis and Dr. Michael Thiel have joined Extera as Vice President and Associate Partner, respectively.
“Jefferson brings to Extera a significant track-record of business development success, most recently as a senior member of the Genzyme Corporate Development team,” said Steven Bernitz, General Partner and Head of Extera’s BioPharma practice. “Furthermore, the addition of Michael expands our on-the-ground transaction capabilities in Europe. Dr. Thiel brings to Extera over 20 years of executive leadership experience, most notably as VP of Strategic Marketing and Business Development at Daiichi Sankyo Europe.”
Transactions led by Jefferson and Michael exceed $2B in aggregate value across all major therapeutic platforms and a wide range of therapeutic areas, and both have considerable experience on the buy-side and sell-side.
Extera Partners is a global life sciences management firm – with offices in the U.S., Europe & Asia – that works hand-in-hand with emerging companies and premier venture investors to capture extraordinary opportunities. Extera specializes in corporate and business development, product commercialization and company turnarounds. For more information, please visit www.exterapartners.com.